Glangle M1 Forte Tablet PR contains a combination of Glimepiride (1mg) and Metformin (1000mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and increases peripheral insulin sensitivity, contributing to reduced blood glucose levels. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or on monotherapy with either agent. The prolonged-release formulation ensures a steady release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with Metformin. Glangle M1 Forte Tablet PR should be used as part of a comprehensive diabetes management plan, including diet modification, physical activity, and regular blood glucose monitoring. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in cases of diabetic ketoacidosis or severe infection. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Regular assessment of renal function and blood glucose levels is recommended to optimize therapy and minimize risks.